

**Company Registration No. 513108 (Eire)**

**RJB BLOODSTOCK LIMITED**  
**ABRIDGED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 APRIL 2025**

# RJB BLOODSTOCK LIMITED

## CONTENTS

---

	<b>Page</b>
Directors' responsibilities statement	1
Directors' declaration	2
Statement of financial position	3
Notes to the financial statements	4 - 8

---

# RJB BLOODSTOCK LIMITED

## DIRECTORS' RESPONSIBILITIES STATEMENT

**FOR THE YEAR ENDED 30 APRIL 2025**

---

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under that law, the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* issued by the Financial Reporting Council (Generally accepted Accounting Practice in Ireland). Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for that financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

On behalf of the board

Justin Carthy  
**Director**

Rachel Carthy  
**Director**

20 March 2026

# **RJB BLOODSTOCK LIMITED**

## **DIRECTORS' DECLARATION ON UNAUDITED FINANCIAL STATEMENTS**

### ***FOR THE YEAR ENDED 30 APRIL 2025***

---

In relation to the financial statements set out on pages 3 to 8:

- The directors approve these financial statements and confirm that they are responsible for them, including selecting the appropriate accounting policies, applying them consistently and making, on a reasonable and prudent basis, the judgments underlying them. They have been prepared on the going concern basis on the grounds that the company will continue in business.
- The directors confirm that they have made available to Browne Murphy & Hughes, all the company's accounting records and provided all the information necessary for the compilation of the financial statements.
- The directors confirm that to the best of their knowledge and belief, the accounting records reflect all transactions of the company for the year ended 30 April 2025.

On behalf of the board

Justin Carthy  
**Director**

Rachel Carthy  
**Director**

20 March 2026

# RJB BLOODSTOCK LIMITED

## STATEMENT OF FINANCIAL POSITION

AS AT 30 APRIL 2025

	Notes	2025 €	€	2024 €	€
<b>Current assets</b>					
Stocks	6	225,000		267,000	
Debtors	7	-		67,601	
Cash at bank and in hand		315,452		211,210	
		<u>540,452</u>		<u>545,811</u>	
<b>Creditors: amounts falling due within one year</b>	8	<u>(1,367,502)</u>		<u>(1,427,810)</u>	
<b>Net current liabilities</b>			<u>(827,050)</u>		<u>(881,999)</u>
<b>Capital and reserves</b>					
Called up share capital presented as equity	9		2		2
Profit and loss reserves	10		<u>(827,052)</u>		<u>(882,001)</u>
<b>Total equity</b>			<u>(827,050)</u>		<u>(881,999)</u>

We, as directors of RJB Bloodstock Limited, state that:

(a) The company is availing itself of the exemption from audit provided for by Chapter 15 of Part 6 of the Companies Act 2014.

(b) The company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied.

(c) The shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2).

(d) The directors acknowledge the obligations of the company, under the Companies Act 2014:

(i) to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a year; and

(ii) to otherwise comply with the provisions of this Act relating to financial statements so far as they are applicable to the company.

(e) The company has relied on the specified exemption contained in section 352 Companies Act 2014; the company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with Financial Reporting Standard 102 'The Financial Statement Reporting Standard applicable in the UK and Republic of Ireland'.

The financial statements were approved by the board of directors and authorised for issue on 20 March 2026 and are signed on its behalf by:

Justin Carthy  
Director

Rachel Carthy  
Director

# RJB BLOODSTOCK LIMITED

## NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 APRIL 2025

---

### 1 Accounting policies

#### Company information

RJB Bloodstock Limited is a limited company domiciled and incorporated in Eire. The registered office is Alderbrook, King Edward Road, Bray, Co Wicklow.

#### 1.1 Accounting convention

These financial statements have been prepared in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102"), as adapted by Section 1A of FRS 102, and the requirements of the Companies Act 2014.

The financial statements are prepared in euros, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest €.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

#### 1.2 Going concern

At the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

#### 1.3 Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

#### 1.4 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Computer equipment	20% Straight Line
--------------------	-------------------

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

#### 1.5 Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

# RJB BLOODSTOCK LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 APRIL 2025

---

### 1 Accounting policies

(Continued)

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

#### 1.6 Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

#### 1.7 Financial instruments

The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's statement of financial position when the company becomes party to the contractual provisions of the instrument.

#### **Basic financial assets**

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs. Financial assets classified as receivable within one year are not amortised.

#### 1.8 Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

#### **Current tax**

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

### 2 Judgements and key sources of estimation uncertainty

In the application of the company's accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

#### **a) Establishing useful economic lives for depreciation of fixed assets.**

The company's accounting policy for depreciation are set out in policy 1.4. The annual depreciation charge depends primarily on the estimated useful economic lives of each type of asset and estimates of residual values. The directors regularly review these asset's useful lives and change them as necessary to reflect current thinking on remaining lives in light of prospective economic utilisation and physical condition of the assets concerned.

# RJB BLOODSTOCK LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 30 APRIL 2025

### 3 Taxation

	2025 €	2024 €
<b>Current tax</b>		
Corporation tax on profits for the current period	8,302	16,783

The actual charge for the year can be reconciled to the expected charge/(credit) for the year based on the profit or loss and the standard rate of tax as follows:

	2025 €	2024 €
Profit/(loss) before taxation	63,251	(615,480)
Expected tax charge/(credit) based on the standard rate of corporation tax of 12.50% (2024: 12.50%)	7,906	(76,935)
Tax effect of expenses that are not deductible in determining taxable profit	-	104,246
Tax losses carried forward utilised	-	(10,528)
Surcharge	396	-
Taxation charge for the year	8,302	16,783

### 4 Tangible fixed assets

	Computer equipment €
<b>Cost</b>	
At 1 May 2024 and 30 April 2025	405
<b>Depreciation and impairment</b>	
At 1 May 2024 and 30 April 2025	405
<b>Carrying amount</b>	
At 30 April 2025	-
At 30 April 2024	-

### 5 Financial instruments

	2025 €	2024 €
<b>Carrying amount of financial assets</b>		
Debt instruments measured at amortised cost	315,452	278,811
<b>Carrying amount of financial liabilities</b>		
Measured at amortised cost	1,356,126	1,407,952

# RJB BLOODSTOCK LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 APRIL 2025

### 6 Stocks

	2025 €	2024 €
Raw materials and consumables	-	42,000
Finished goods and goods for resale	225,000	225,000
	<u>225,000</u>	<u>267,000</u>

### 7 Debtors

	2025 €	2024 €
<b>Amounts falling due within one year:</b>		
Other debtors	-	67,601
	<u>-</u>	<u>67,601</u>

### 8 Creditors: amounts falling due within one year

	2025 €	2024 €
Trade creditors	237,963	176,137
Corporation tax	8,301	16,783
Other creditors	1,118,163	1,231,815
Accruals	3,075	3,075
	<u>1,367,502</u>	<u>1,427,810</u>

### 9 Share capital

	2025 €	2024 €
<b>Ordinary share capital</b>		
<b>Authorised equity</b>		
100,000 Ordinary Shares of €1 each	100,000	100,000
	<u>100,000</u>	<u>100,000</u>
<b>Issued and fully paid equity</b>		
2 Ordinary Shares of €1 each	2	2
	<u>2</u>	<u>2</u>

### 10 Profit and loss reserves

	2025 €	2024 €
At the beginning of the year	(882,001)	(249,738)
Profit/(loss) for the year	54,949	(632,263)
	<u>(827,052)</u>	<u>(882,001)</u>

# **RJB BLOODSTOCK LIMITED**

## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**

***FOR THE YEAR ENDED 30 APRIL 2025***

---

### **11 Related party transactions**

At the beginning of the year one of the directors was owed €1,026,390 by the company. During the year the director advanced €954,610 to the company, while the company made repayments of €862,837 to the director. At 30th April 2025 the company owed the director €1,118,163.

### **12 Ultimate controlling party**

The company is controlled by its directors Justin and Rachel Carthy.

### **13 Approval of financial statements**

The directors approved the financial statements on 20 March 2026.